Cleveland Clinic Innovations has formed a spin-off company, Cleveland Diagnostics Inc., to develop and commercialize cancer diagnostics and screening tests.

Cleveland Diagnostics is developing technology that focuses on protein biomarker structural changes that correlate with the presence of a disease. The company’s pipeline of actionable non-invasive cancer diagnostic assays includes blood-based tests, initially concentrating on prostate, breast and ovarian cancer.

“Cleveland Clinic has a 90-year history of encouraging discovery and enabling physicians and researchers to create technologies that benefit patients,” said Thomas J. Graham, M.D., Cleveland Clinic’s Chief Innovation Officer. “When fully developed, Cleveland Diagnostics’ unique screenings will provide physicians and patients with the information they need to make decisions on treatments.”

Cleveland Clinic Innovations formed the new company with AnalizaDx LLC, which has been working to develop the technology platform through early clinical development and validation.

“Early and effective diagnosis is critical in cancer. The rapidly changing healthcare system is placing a premium on cost-effective, clinically useful tools, and we intend to deliver clinically actionable and affordable cancer tests to patients and their healthcare providers, and make an important and lasting impact in the field,” said Arnon Chait, Ph.D., who led AnalizaDx and will serve as CEO of Cleveland Diagnostics.